logo
‘Amazing' reduction in Alzheimer's risk verified by blood markers, study says

‘Amazing' reduction in Alzheimer's risk verified by blood markers, study says

Yahoo08-04-2025

Editor's Note:CNN Chief Medical Correspondent Dr. Sanjay Gupta and writer Sandee LaMotte are part of the study covered in this story and have written about their experiences.
When Penny Ashford's father was diagnosed with early-stage Alzheimer's disease at age 62, she knew the devastating brain disorder might one day steal her memory. In her late 50s, her free-floating anxiety turned to outright panic when she began struggling to find words.
'I couldn't tell a story. I couldn't get my words out,' said Ashford, now 61. 'I remember sitting at a dinner party one time, and I couldn't finish my thoughts. It was the most unbelievable moment.
'I came home and sobbed and told my husband, 'Something is wrong with me. I can't talk,'' she said. 'I was petrified.'
Today, after a complete revamp of her lifestyle and overall health, Ashford's struggles with retrieving words have eased, while measures of amyloid and tau proteins and neuroinflammation — all hallmark signs of Alzheimer's — have fallen.
Ashford knows about these improvements because she's part of a unique study tracking her progress via key blood biomarkers now being used to help diagnose early dementia. Instead of relying on painful spinal taps and expensive brain scans, these blood tests are heralded as a new, less invasive and time-consuming way to determine risk and aid in an earlier diagnosis of Alzheimer's.
The preliminary data, presented Monday at the American Academy of Neurology annual meeting in San Diego, analyzed biomarkers on 54 participants in an ongoing preventive neurology study called the Biorepository Study for Neurodegenerative Diseases, or BioRAND.
'The field is primarily using various biomarkers to determine if you have dementia or not,' said lead study author Dr. Kellyann Niotis, a preventive neurologist who researches risk reduction for Alzheimer's and Parkinson's diseases at the Institute for Neurodegenerative Diseases in Boca Raton, Florida.
'No one is really looking at the changes in these biomarkers as outcome measures, as a way of tracking progress in a person's journey to improve their brain,' Niotis said. 'We believe these biomarkers may show how the disease progression is being modified biologically by a person's actions.'
Alzheimer's blood tests are the key to widespread prevention of dementia, experts say. If people can be diagnosed in their doctor's office, they can more immediately move into preventive care and implement lifestyle changes designed to slow the progression of their disease.
The problem, said senior study author Dr. Richard Isaacson, is the variability in how well these new blood biomarker tests work to predict or track disease progression.
'There is a dirty little secret in the Alzheimer's blood testing community where so many testing platforms, biotech companies, and a flurry of new blood tests are released,' Isaacson said, 'but it's unclear which of these tests are most accurate to track progression and evaluate response to therapies to slow progression toward dementia.'
To address this gap, Isaacson's research team and collaborators at five sites across the United States and Canada set forth to evaluate and eventually cross-compare the clinical use of what the neurologist said he believes will one day become 'the cholesterol test for the brain.'
'In the not so far future, people in their 30s, 40s, 50s, 60s and beyond will get a baseline test to evaluate risk and help track progress over time — similar to how traditional cholesterol tests are used today,' said Isaacson, founder of one of the first Alzheimer's prevention clinics in the United States.
'Our eventual goal is to offer a blood panel at cost to help democratize access and broaden the ability for people to receive care,' he added.
Measuring levels of both amyloid and tau is key to understanding and diagnosing Alzheimer's and other forms of dementia.
Amyloid plaques play a key role in the development of Alzheimer's when small clusters gather at synapses in the brain and interfere with the nerve cells' ability to communicate. Such plaques are thought to trigger changes in tau proteins, which form into tangles in parts of the brain controlling memory.
Tau tangles are also implicated in other neurological diseases such as frontal lobe dementia, or FTD, and Lewy body dementia in which abnormal clumps of a protein called alpha-synuclein accumulate in the brain's neurons.
The biomarker plasma phosphorylated tau 217, or p-tau217 for short, is a top contender in the diagnosis of mild cognitive impairment and early-stage Alzheimer's disease. Its cousin, p-tau 181, is also a helpful indicator.
P-tau 217 is a 'beautiful marker for Alzheimer's,' Dr. Maria Carrillo, chief science officer of the Alzheimer's Association, told CNN in an earlier interview.
'You're not really measuring amyloid, but the test is telling you it's there, and that's been backed up with objective PET (positron emission tomography) scans that can see amyloid in the brain,' Carrillo said. '… If you have elevated tau in your brain, however, then we know that's a sign of another type of dementia.'
Another biomarker test is the amyloid 42/40 ratio scan, which measures two types of amyloid proteins, another key biomarker of Alzheimer's disease. At times, such tests work best when used together. In an earlier study, a combination of both amyloid and p-tau 217 tests, called the amyloid probability score, showed a 90% accuracy rate in determining whether memory loss is due to Alzheimer's disease.
Glial fibrillary acidic protein, or GFAP, and neurofilament light chain, or NfL, which indicate brain inflammation and degenerative decay, are also helpful in tracking the progression of Alzheimer's disease. Dozens more biomarkers are being tested in labs around the world.
Isaacson's team at the Institute for Neurodegenerative Diseases is studying more than 125 individual markers from a variety of commercial and research-based tests, some of which may soon be available in a clinical setting.
Why investigate so many? Because personalized medicine may demand it, Niotis said.
'Neurodegenerative diseases present so differently in different people,' she said. 'It may be we will need a very nuanced, individualized approach in clinical practice to monitor the effectiveness of what we're doing for a given patient.'
The ongoing preventive neurology study called BioRAND reported on 71 participants, with biomarkers being analyzed on 54 people. The other 17 people served as the control group.
The group of 54 received a series of personalized lifestyle recommendations designed to improve their brain. Such interventions have been shown in past research to improve memory and thinking skills by five points on a cognitive test for people with mild cognitive impairment.
The recommendations include a focus on blood pressure control, diet, exercise, stress reduction, sleep hygiene and weight control as well as addressing metabolic, hormonal and nutrient imbalances. Medications, vitamins and supplements are tailored to each person's unique needs.
Similar to a 2019 study led by Isaacson and Niotis, people who fulfilled at least 60% of the lifestyle recommendations were considered high compliance, while those who implemented less than 60% were low compliance. Periodic blood tests tracked progress in various brain biomarkers.
The outcome? The more work people put into change, the better their brains. Just look at Penny Ashford.
'My blood work was terrible; my eating habits were terrible. I didn't exercise, so my muscle tone was really bad — I had no muscles in my bottom or on my thighs,' Ashford said.
'I got the lecture of a lifetime,' she said. 'They told me, 'Your window is closing, your markers are so bad. Either you've got to do this, or you're done.''
A lifelong sugar addict, Ashford stopped eating sweets.
'I used to think I had a chemical imbalance because I was such a crazy freak about sugar — I could polish off a whole bag of Oreos, no problem, and I love ice cream,' Ashford said.
'I haven't had a dessert. I haven't had ice cream. I haven't had anything except fruit since a year ago March.'
She began an intense exercise program of cardio and resistance training, along with yoga for stress reduction, and moved to a plant-based Mediterranean style of eating. Under a doctor's supervision, she added supplements and vitamins to boost energy and lower stress.
'She was a 10 out of 10 with her diet and exercise,' Niotis said. 'She lost around 30 pounds and gained lean muscle mass. It was amazing.'
A year later, Ashford's blood biomarkers told a completely different story about her brain health. Her p-tau 217 dropped by 43% and her p-tau 181 by 75%.
'We also looked at GFAP and neurofilament light, the markers of neuroinflammation and neurodegeneration,' Niotis said. 'Penny's GFAP went down by 66% and her NfL went down by 84%.
'These are really impressive changes in these markers of neuronal health,' she said. 'And the best part about it is it really did track with her clinical symptoms. Her word retrieval problems improved, and she felt so much better.'
Ashford wasn't the only top performer in the study. Blood biomarkers also significantly improved across the entire group given risk reduction advice, Isaacson said, even those who were not as committed as Ashford.
'I've lost count on how many people have shown blood markers of brain disease trend in the right direction, but every time it amazes me,' he said. 'For over 20 years, I was told that what is happening right in front of my eyes was impossible, but the patients' stories, clinical improvements and test results speak for themselves.'
Much more work remains before blood testing for Alzheimer's becomes a routine part of clinical practice, Isaacson said.
'Our group has a saying, 'Promise not to overpromise.' By this we mean it's critical to be transparent about the current limitations of these tests, and the variability across different platforms,' he said.
While science works out the kinks, Ashford counts herself lucky to be able to track changes in her biomarker numbers — a key motivator in her journey toward better brain health.
'It's huge, huge,' she said. 'I'm so proud of myself. And each success that I have empowers me to do more, keep going and not let up.
'I look back at my dad. He didn't have any of these options. I watched my dad deteriorate, and I thank God, I am so lucky. We are so lucky.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Get Ready to Hear a Lot More About Your Mitochondria
Get Ready to Hear a Lot More About Your Mitochondria

Atlantic

time3 hours ago

  • Atlantic

Get Ready to Hear a Lot More About Your Mitochondria

Robert F. Kennedy Jr.'s warning about mitochondria slipped in between the anti-vaccine junk science and the excoriation of pharmaceutical drugs as 'the No. 3 killer in our country.' He was speaking in 2023 to Joe Rogan, elaborating on the dangers of Wi-Fi—which no high-quality scientific evidence has shown to harm anyone's health—and arguing that it causes disease by somehow opening the blood-brain barrier, and by degrading victims' mitochondria. The mention of mitochondria—the tiny structures that generate energy within our cells—was brief. Two years later, mitochondrial health is poised to become a pillar of the MAHA movement, already showing up in marketing for supplements and on podcasts across the 'manosphere.' Casey Means, President Donald Trump's newest nominee for surgeon general, has singled out the organelle as the main casualty of the modern American health crisis. According to Means (who has an M.D. but no active medical license), most of America's chronic ailments can be traced to mitochondrial dysfunction. Should she be confirmed to the post of surgeon general, the American public can expect to hear a lot more about mitochondria. Among scientists, interest and investment in mitochondria have risen notably in the past five years, Kay Macleod, a University of Chicago researcher who studies mitochondria's role in cancer, told me. Mitochondria, after all, perform a variety of crucial functions in the human body. Beyond powering cells, they can affect gene expression, help certain enzymes function, and modulate cell death, Macleod said. When mitochondria are defective, people do indeed suffer. Vamsi Mootha, a mitochondrial biologist based at Massachusetts General Hospital and the Broad Institute, told me that rare genetic defects (appearing in about one in 4,300 people) can cause the organelles to malfunction, leading to muscle weakness, heart abnormalities, cognitive disability, and liver and kidney problems. Evidence also suggests that defects in mitochondria directly contribute to symptoms of Parkinson's disease, and could be both a cause and an effect of type 2 diabetes. Other conditions' links to mitochondria are blurrier. Researchers see aberrant mitochondria in postmortem biopsies of patients with illnesses such as Alzheimer's, cancer, and fatty-liver disease, Mootha said; whether those damaged mitochondria cause or result from such conditions is not yet clear. But according to Good Energy, the book Means published last year with a top MAHA adviser—her brother, Calley—mitochondrial dysfunction is a veritable plague upon the United States, responsible for both serious illness and everyday malaise. In their view, modern Western diets and lifestyles wreck countless Americans' metabolic health: Every time you drink unfiltered water or a soda, or feel the stress of mounting phone notifications, you hurt your mitochondria, they say, triggering an immune response that in turn triggers inflammation. (Damaged mitochondria really can cause inflammation, Macleod said.) This chain of events, the Meanses claim, can be blamed for virtually every common chronic health condition: migraines, depression, infertility, heart disease, obesity, cancer, and more. (Casey Means did not respond to requests for comment; reached by email, Calley did not respond to my questions about mitochondria, but noted, 'There is significant scientific evidence that healthy food, exercise and sleep have a significant impact on reversing chronic disease.') Good Energy follows a typical wellness playbook: using a mixture of valid and dubious research to pin a slew of common health problems on one overlooked element of health—and advertising a cure. Among the culprits for our mitochondrial ravaging, according to the Meanses, are poor sleep, medications, ultraprocessed foods, seed oils, too many calories, and too few vitamins, as well as chronically staying in comfortable ambient temperatures. The Means siblings therefore recommend eschewing refined sugar in favor of leafy greens, avoiding nicotine and alcohol, frequenting saunas and cold plunges, getting seven to eight hours of uninterrupted sleep a night, and cleansing your life of environmental toxins. Some studies indeed suggest that mitochondrial function is linked with sleep and temperature, but they've all been conducted on cell cultures, organoids, or mice. According to Macleod, evidence suggests that diet, too, is likely important. But only one lifestyle intervention— exercise —has been definitively shown to improve mitochondrial health in humans. The Meanses are riding a wave of interest in mitochondrial health in the wellness world. Earlier this year, the longevity influencer Bryan Johnson and the ivermectin enthusiast Mel Gibson both endorsed the dye methylene blue for its power to improve mitochondrial respiration; Kennedy was filmed slipping something that looks a lot like methylene blue into his drink. (Kennedy did not respond to a request for comment; the FDA has approved methylene blue, but only as a treatment for the blood disease methemoglobinemia.) AG1, formerly known as Athletic Greens, formulates its drinkable vitamins for mitochondrial health. Even one laser-light skin treatment promises to 'recharge failing mitochondria.' The enzyme CoQ10 is popular right now as a supplement for mitochondrial function, as is NAD, a molecule involved in mitochondria's production of energy. NAD IV drips are especially beloved by celebrities such as Gwyneth Paltrow, Kendall Jenner, and the Biebers. These supplements are generally thought to be safe, and some preliminary research shows that NAD supplementation could help patients with Parkinson's or other neurodegenerative diseases, and that CoQ10 could benefit people with mitochondrial disorders. Patients whose symptoms are clearly caused or made worse by deficiencies in a specific vitamin, such as thiamine, can benefit from supplementing those vitamins, Mootha said. But little research explores how these supplements might affect healthy adults. In Good Energy, as well as on her website and in podcast appearances, Casey Means promotes a number of supplements for mitochondrial health. She also recommends that people wear continuous glucose monitors—available from her company, Levels Health, for $184 a month—to help prevent overwhelming their mitochondria with too much glucose. (According to Macleod, glucose levels are only 'a very indirect measure' of mitochondrial activity.) As with so many problems that wellness influencers harp on, the supposed solution to this one involves buying products from those exact same people. At best, all of this attention to mitochondria could lead Americans to healthier habits. Much of the advice in Good Energy echoes health recommendations we've all heard for decades; getting regular exercise and plenty of fiber is good guidance, regardless of anyone's reasons for doing so. Switching out unhealthy habits for healthy ones will likely even improve your mitochondrial health, Jaya Ganesh, a mitochondrial-disease expert at Icahn School of Medicine at Mount Sinai, told me. After all, 'if you consistently beat your body up with unhealthy habits, everything is going to fall sick,' Ganesh said. But the mitochondrial approach to wellness carries risks, too. For patients with genetically caused mitochondrial disease, lifestyle changes might marginally improve some symptoms, Ganesh said, but attempting to cure such conditions with supplements and a healthy diet alone could be dangerous. Means also calls out medications—including antibiotics, chemotherapy, antiretrovirals, statins, and high-blood-pressure drugs—for interfering with mitochondria. Macleod told me that statins really do affect mitochondria, as do some antibiotics. (The latter makes sense: Mitochondria are thought to have evolved from bacteria more than a billion years ago.) That's no reason, though, to avoid any of these medications if a doctor has determined that you need them. And yet, a whole chapter of Good Energy is dedicated to the idea that readers should mistrust the motives of their doctors, who the authors say profit by keeping Americans sick. The book is less critical of the ways the wellness industry preys on people's fears. Zooming in on mitochondria might offer a reassuringly specific and seemingly scientific explanation of the many real ills of the U.S. population, but ultimately, Means and MAHA are only helping obscure the big picture.

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Yahoo

time3 hours ago

  • Yahoo

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. ContactsTrista Morrison, tmorrison@ Investors: Sarah McCabe, smccabe@ Brooke Shenkin, brooke@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

1 in 10 Hoosiers over 65 has Alzheimer's
1 in 10 Hoosiers over 65 has Alzheimer's

Axios

time5 hours ago

  • Axios

1 in 10 Hoosiers over 65 has Alzheimer's

Nearly 11% of Hoosiers over 65 are living with Alzheimer's — more than 121,300 people — according to 2020 data shared in a new Alzheimer's Association report. Why it matters: More than 7 million American seniors now live with Alzheimer's, the highest number ever recorded, but addressing cognitive decline early can help stave off the disease. By the numbers: Almost two-thirds of Americans with Alzheimer's are women, per data cited in the report. Risk increases with age: 5.1% of people ages 65–74 have it, while a third of people 85 and older have it, per the report. Zoom in: Indiana's elderly population is expected to grow rapidly in the coming years, according to projections from the Indiana Business Research Center at Indiana University's Kelley School of Business. One in every five Hoosiers (over 966,000 people) will be 65 or older by 2030. Marion County skews a bit younger. The elderly population percentage is here is poised to reach 16.2% in 2030. Stunning stat: The research center says the number of people 65 and up in Indiana will surpass 1.5 million by 2050, a 57% increase from 2015. Threat level: Nearly 18% of Hoosiers 45 and older already have subjective cognitive decline, according to the Alzheimer's Association. And the burden of care is often thrust onto family members. The Alzheimer's Association estimates about 219,000 Indiana caregivers provide unpaid care valued at $6.9 billion for loved ones with the disease. Zoom out: The highest rates of seniors with Alzheimer's are in D.C. (16.8%) and Maryland (12.9%). The lowest is in Alaska (8.8%). What they're saying: "It doesn't surprise me" that Alzheimer's incidence has increased, because the population is aging and "we're becoming more sophisticated in our options for diagnosing and testing for Alzheimer's disease," Lakelyn Eichenberger, a gerontologist and caregiving advocate at Home Instead, tells Axios. With cases climbing and age a key risk factor, early action is critical for managing the disease and accessing new treatments, Eichenberger says. Warning signs to watch for in high-risk age groups: Trouble finding the right word. Difficulty judging distances. Misplacing things and struggling to retrace steps. Between the lines: "If you're seeing patterns of these types of signs over an extended period of time," that could mean it's time to see a doctor about cognitive decline, Eichenberger says.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store